

The merchandise is currently classifiable under Harmonized Tariff Schedule of the United States (HTSUS) subheadings 2915.70.0110, 2915.70.0120, 2915.70.0150, 2915.90.1010, 2915.90.1050, 2916.15.1000, 2916.15.5100, 3823.11.0000, 3823.12.0000, 3823.19.2000, and 3823.19.4000 and may also enter under 3824.99.4190.

The HTSUS subheadings set forth above are provided for convenience and customs purposes only. The written description of the scope is dispositive.

Appendix II

List of Topics Discussed in the Preliminary Decision Memorandum

- I. Summary
- II. Background
- III. Injury Test
- IV. Diversification of Indonesia's Economy
- V. Subsidies Valuation
- VI. Benchmarks and Interest Rates
- VII. Analysis of Programs
- VIII. Recommendation

[FR Doc. 2026-14871 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2026-0499]

Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride

AGENCY: United States Patent and Trademark Office; Department of Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 8,461,196 ('196 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

On July 7, 2026, Otsuka Pharmaceutical Co., Ltd., the agent of the owner of record of the '196 patent,

i.e., Otsuka America Pharmaceutical, Inc., timely filed an application under 35 U.S.C. 156(d)(5) for a first interim extension of the term of the '196 patent. The '196 patent claims the drug product centanafadine hydrochloride. The application indicates that a RRP as described in 35 U.S.C. 156(g)(1)(B)(ii) for centanafadine hydrochloride is ongoing before the Food and Drug Administration for permission to market and use the drug product commercially.

Review of the application indicates that, except for permission to market or use the drug product commercially, the '196 patent would be eligible for an extension of its term under 35 U.S.C. 156. Because it appears reasonable to expect that the RRP will continue beyond the original expiration date of the '196 patent, *i.e.*, July 25, 2026, interim extension of the patent's term under 35 U.S.C. 156(d)(5) is appropriate.

A first interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 8,461,196 is granted for a period of one year from the original expiration date of the patent.

Stefanos Karmis,

Acting Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2026-14941 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2026-0497]

Grant of Interim Extension of the Term of U.S. Patent No. 9,737,506; Centanafadine Hydrochloride

AGENCY: United States Patent and Trademark Office; Department of Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 9,737,506 ('506 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be

extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

On July 7, 2026, Otsuka Pharmaceutical Co., Ltd., the agent of the owner of record of the '506 patent, *i.e.*, Otsuka America Pharmaceutical, Inc., timely filed an application under 35 U.S.C. 156(d)(5) for a first interim extension of the term of the '506 patent. The '506 patent claims methods of using the drug product centanafadine hydrochloride. The application indicates that a RRP as described in 35 U.S.C. 156(g)(1)(B)(ii) for centanafadine hydrochloride is ongoing before the Food and Drug Administration for permission to market and use the drug product commercially.

Review of the application indicates that, except for permission to market or use the drug product commercially, the '506 patent would be eligible for an extension of its term under 35 U.S.C. 156. Because it appears reasonable to expect that the RRP will continue beyond the original expiration date of the '506 patent, *i.e.*, July 25, 2026, interim extension of the patent's term under 35 U.S.C. 156(d)(5) is appropriate.

A first interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 9,737,506 is granted for a period of one year from the original expiration date of the patent.

Stefanos Karmis,

Acting Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2026-14940 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2026-0496]

Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride

AGENCY: United States Patent and Trademark Office; Department of Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 8,877,798 ('798 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or raul.tamayo@uspto.gov.